Physician profile
Travis Walling
NPI 1114329497
$3,545.21
in general payments reported to CMS, 2019-2025
25 companies · $104 in 2025
The $104 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $699 · 2022: $1,411 · 2023: $1,136 · 2024: $195 · 2025: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,435.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $645.19 | 2021-2024 | |
| Glaxosmithkline, LLC. | $484.34 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $386.54 | 2021-2025 | Evenity, Prolia, Otezla |
| Pfizer INC. | $313.30 | 2021-2024 | |
| Novo Nordisk INC | $244.07 | 2021-2024 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $181.64 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $171.29 | 2022 | |
| Lilly USA, LLC | $148.20 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $131.52 | 2021-2023 | Farxiga |
| Abbott Laboratories | $119.10 | 2022-2025 | Freestyle Libre, Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $111.03 | 2021-2023 | Spravato, Xarelto |
| Astellas Pharma US INC | $106.47 | 2021-2024 | Veozah, Myrbetriq |
| Alfasigma USA, INC. | $89.86 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $84.78 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.95 | 2022-2023 | Trulance, Xifaxan |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $53.47 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.37 | 2021-2025 | Glassia |
| Merck Sharp & Dohme LLC | $29.96 | 2021 | |
| Esperion Therapeutics, INC. | $28.66 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.41 | 2021-2023 | Jardiance |
| Philips North America LLC | $19.79 | 2025 | Vest Therapy Und |
| Exact Sciences Corporation | $16.74 | 2023 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $15.62 | 2024 | Rexulti |
| Regeneron Healthcare Solutions, INC. | $14.80 | 2025 | Dupixent |
| Sanofi-Aventis U.S. LLC | $12.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Walling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.